Francisco Trust Under Agreemen Sells 40,000 Shares of Dyadic International (NASDAQ:DYAI) Stock

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 40,000 shares of the business’s stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $1.98, for a total value of $79,200.00. Following the completion of the transaction, the insider directly owned 3,410,664 shares of the company’s stock, valued at approximately $6,753,114.72. This trade represents a 1.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Dyadic International Price Performance

DYAI opened at $0.94 on Monday. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.42 and a current ratio of 2.42. The stock has a market capitalization of $34.27 million, a P/E ratio of -4.09 and a beta of 1.15. The company’s 50-day simple moving average is $0.77 and its two-hundred day simple moving average is $0.83. Dyadic International Inc. has a 52-week low of $0.65 and a 52-week high of $1.35.

Dyadic International (NASDAQ:DYAI) last announced its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. The company had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $0.90 million. As a group, analysts predict that Dyadic International Inc. will post 0.13 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Apis Capital Advisors LLC bought a new stake in shares of Dyadic International during the 3rd quarter valued at about $1,817,000. Geode Capital Management LLC boosted its holdings in shares of Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after buying an additional 36,266 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new position in shares of Dyadic International in the third quarter worth approximately $190,000. Marathon Capital Management grew its position in Dyadic International by 142.9% during the fourth quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 50,000 shares during the period. Finally, Bank of America Corp DE grew its position in Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 26,965 shares during the period. Institutional investors own 27.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a research report on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Dyadic International has a consensus rating of “Hold” and a consensus target price of $3.00.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.